Visceral leishmaniasis in Lebanon a report of four cases: case series and review

Oussaima Eldbouni1, Pierre Abihanna1, Mona Beaini2, Afaf Minari1, Ibrahim Khalife3, Gladys Gemayel4

1 Departement of internal medicine infectious diseases division, Rafic Hariri University Hospital, Beirut, Lebanon
2 Departement of laboratory, Rafic Hariri University Hospital, Beirut, Lebanon
3 Departement of pediatric Hematology oncology division, Rafic Hariri University Hospital, Beirut, Lebanon
4 Departement of pathology and laboratory, American University of Beirut, Beirut, Lebanon

Abstract
Introduction: Leishmaniasis comprises a complex of vector-borne diseases, caused by more than 20 species of the protozoan genus Leishmania, and ranging from localized skin ulcers to lethal systemic disease. It is endemic in Asia, Africa, the Americas, and the Mediterranean region. In the Middle East countries like Syria reports high incidence of the disease. In addition to the endemicity of the region for leishmaniasis, the Middle East has seen a great deal of human migration either for earning of livelihood or due to political upheaval in the region. Cutaneous form can be disfiguring but visceral form can be lethal.
Methodology: In this article we report the clinical presentation of 4 cases of visceral leishmaniasis; 3 cases were pediatrics and one immunosuppressed adult patient all of them were from Syria from different regions. The diagnosis was made by bone marrow aspirate; PCR was made for 2 of them and was positive for leishmania infantum. All of them were treated with Amphotericin B lipid formulation (ABELCET) with complete response (definite cure).
Results: We report in this article 4 cases of visceral leishmaniasis treated with amphotericin B lipid complex (Abelcet) following the guidelines with complete remission.
Conclusion: Visceral leishmaniasis is a serious disease and if not treated can lead to death. Lebanon is not known to be endemic for leishmania but since the war the ministry of health reported an outbreak of leishmania and mainly cutaneous leishmania. Here we present 4 cases of visceral leishmania and a review of the latest guidelines on the treatment modalities and protocols.

Keywords: Visceral leishmania; leishmania cases; Amphotericin B lipid complex.


(Received 09 January 2018 – Accepted 18 January 2018)

Copyright © 2018 Eldbouni et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author
Eldbouni Oussaima, MD
Internal medicine department, infectious diseases division, Rafic Hariri University Hospital, Khanssa street, Bir Hassan, Beirut, Lebanon
Phone: 009613661326
Email: oussayma_dbouni@yahoo.com

Conflict of interests: No conflict of interests is declared.